CHF61.20 after-hours dip: Sandoz Group AG (SDZ.SW) on SIX, monitor catalysts

SDZ.SW stock is trading at CHF61.20 after-hours on 11 Mar 2026, down 4.29% (-CHF2.74) on volume of 1,306,605 shares, making Sandoz Group AG one of the most active names on the SIX in Switzerland. The decline follows a weaker session high of CHF63.04 and leaves the share price below its 50-day average of CHF62.97 but above the 200-day mean of CHF52.83. Traders are watching earnings cadence, biosimilars demand and margin trends as catalysts that could re-rate the stock in coming weeks.

SDZ.SW stock: after-hours volume and price action

Sandoz Group AG (SDZ.SW) closed the regular session at CHF63.94 and is at CHF61.20 after-hours, a -4.29% move that pushed intraday low to CHF60.94. Volume today reached 1,306,605 shares versus an average of 789,484, a relative volume of 1.29 that confirms the stock’s ‘most active’ status on SIX. The combination of heightened volume and price weakness suggests active profit-taking rather than a liquidity vacuum.

Valuation and fundamentals snapshot for SDZ.SW stock

Sandoz reports EPS CHF1.62 and a trailing PE of 39.15, above the Swiss healthcare sector average PE of 30.19. Price to book is 3.74 and EV/EBITDA sits near 24.02, indicating a premium multiple driven by growth expectations in biosimilars. The company shows a dividend per share of CHF0.77 and a payout ratio near 34.29%, but free cash flow yield is low at 0.90%, highlighting valuation risk if growth slows.

Technical picture and trading signals for SDZ.SW stock

Momentum indicators are mixed: RSI at 46.48 sits near neutral while MACD histogram is negative, signaling short-term pressure. Bollinger lower band at CHF61.65 is close to the current price and ATR is CHF2.20, implying elevated short-term volatility. The 50-day average (CHF62.97) provides immediate resistance and a close above CHF66.28 (BB middle) would confirm short-term recovery. Traders should note an oversold CCI at -147.36 and an ADX of 27.57, which points to a strong trend in place.

SDZ.SW stock risks and opportunities

Key opportunities include expanding biosimilars sales and manufacturing contract wins that can improve margins and cash flow. Risks include a high PE relative to peers, inventory days of 176.02 that pressure working capital, and exposure to pricing pressure in generics. Net debt to EBITDA of 2.42 and debt/equity of 0.61 are manageable but limit leverage flexibility during a growth slowdown.

Meyka AI rates SDZ.SW with a score out of 100 and forecast

Meyka AI rates SDZ.SW with a score out of 100: 70.59, Grade B+, Suggestion BUY. This grade factors in S&P 500 and sector comparisons, industry metrics, financial growth, key ratios, forecast outputs and analyst consensus. Meyka AI’s forecast model projects a monthly target of CHF62.50, quarterly CHF68.16 and yearly CHF85.98, implying an upside of 40.49% from the current CHF61.20. Forecasts are model-based projections and not guarantees.

Analyst outlook and price targets for SDZ.SW stock

Consensus price targets are limited; Meyka AI uses scenario bands: a near-term support target at CHF56.00, a base 12-month target of CHF68.00, and a bullish 12-month target aligned to the model at CHF86.00. These targets reflect expected revenue recovery and biosimilar uptake. The company reports earnings next on 2026-08-05, which will be a key update for guiding 2027 expectations.

Final Thoughts

Sandoz Group AG (SDZ.SW) is a most-active SIX stock on 11 Mar 2026 after falling to CHF61.20 on strong turnover of 1,306,605 shares. Valuation is rich with a trailing PE of 39.15 and EV/EBITDA near 24.02, while operational metrics show solid ROE of 10.09% and manageable net debt to EBITDA of 2.42. Meyka AI’s forecast model projects a 12-month level of CHF85.98, implying 40.49% upside versus the current price; this represents the platform’s base-case outlook but not a guarantee. Investors should weigh premium multiples and inventory-driven cash conversion cycle of 152.10 days against biosimilar growth potential. For active traders, the technical setup favors watching a reclaim of CHF66.28 for momentum confirmation. For longer term investors, monitor upcoming earnings, biosimilars uptake and margins before adding exposure. Source company filings at Sandoz and market context at Investing.com. Meyka AI provides this analysis as an AI-powered market analysis platform and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.